Abstract:The optimal choice of post-operative treatment mode for resectable limited-stage small cell lung cancer (SCLC) is controversial in clinical practice. Different treatment modes may have different effects on prognosis of small cell lung cancer after resection. Data from a total of 122 patients with limited-stage SCLC undergoing operation were collected at our Cancer Hospital from 2012 to 2016. Clinical and pathological features, and treatment modes (including surgical methods, postoperative adjuvant radiotherapy and chemotherapy, prophylactic brain radiotherapy, etc.) were compared in small cell lung cancer after resection. The survival outcomes among different factors were analyzed by Kaplan-Meier method, and the survival differences among different factors were compared by log-rank method. Multivariate cox regression analysis was used to explore independent prognostic factors. The median follow-up time was 54.23 months. Among 122 patients, the 1-, 3- and 5-year overall survival (OS) rates were 95.08%, 75.14% and 63.79%, respectively. The 1-, 3- and 5-year recurrence-free survival (RFS) rates were 80.99%, 66.62% and 61.86%, respectively. Recurrences were diagnosed in 56 (45%) patients, including 22 (39%) with brain metastasis, 15 (27%) with intrapulmonary recurrence, 7 (13%) with bone metastasis, 6 (11%) with hepatic metastasis, and 6 (11%) with other metastasis. Operation patterns affected OS. 116 patients received lobectomy and 6 patients received pneumonectomy. Median OS of these two groups were 68.37 and 35.37 months, respectively (p = 0.028). The T stage affected the postoperative OS. The median OS of T1、T2、T3 were 65.87, 71.29 and 29.92 months, respectively (p = 0.021). The disease-free survival (PFS) and OS of patients receiving adjuvant chemotherapy or combined with radiotherapy were longer than those receiving surgery only. The median PFS of adjuvant chemotherapy group, chemotherapy and radiotherapy combination group, and simple surgery group were 69.01, 53.87 and 19.37 months, respectively (p=0.002). Accordingly, the median OS were 70.6, 65.56 and 30.8 months (p=0.002). Patients with postoperative prophylactic cranial irradiation (PCI) had a longer OS than those without PCI (62.28 vs. 78.84 months, p=0.028). As for patients with resectable limited-stage SCLC，the 5-year survival rate of patients with surgery is higher than those without. Lobectomy is the optimal surgery mode, and adjuvant chemotherapy combined with prophylactic cranial irradiation after operation can significantly prolong the OS.

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Adjuvant Treatment for Patients with Incidentally Resected Limited Disease Small Cell Lung Cancer—a Retrospective Study

Impact of Adjuvant Therapy on Survival in Surgically Resected Limited-Stage Small Cell Lung Cancer

The Role of Adjuvant Chemotherapy in Early-Stage Combined Small-Cell Lung Cancer

Clinical Effect of Postoperative Chemoradiotherapy in Resected Advanced Laryngeal Squamous Cell Carcinoma.

Retrospective study of surgical resection in the treatment of limited stage small cell lung cancer

[Outcomes and the Role of Adjuvant Therapy of Limited Stage Small Cell Lung Cancer Undergoing Surgical Treatment].

Survival Analysis of Patients with Non-Small Cell Lung Cancer Who Underwent Surgical Resection Following 4 Lung Cancer Resection Guidelines.

Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease

Adjuvant Treatment Can Improve Prognosis in Patients with Non-Small Cell Lung Cancer ≤3 Cm after Sublobectomy: a Propensity Score Analysis

Role of Surgery in Potentially Resectable Small‐Cell Lung Cancer Based on the Eighth Edition of the TNM Classification: A Population Study of the US SEER Database

Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer

Lung resection after initial nonoperative treatment for non-small cell lung cancer

Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients

Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancer

Prognostic factors of patients with small cell lung cancer after surgical treatment

EP1.12-11 Effect of Treatment Mode on Prognosis of Resectable Limited-Stage Small Cell Lung Cancer

The Clinical Role of Adjuvant Chemotherapy after Sublobar Resection for Non-Small-Cell Lung Cancer ≤ 20 mm with Lymph Node Metastases: A Propensity-Matched Analysis of the National Cancer Database

Retrospective Study of Surgery Versus Non-Surgical Management in Limited-Disease Small Cell Lung Cancer

Impact of treatment modality on long-term survival of stage IA small-cell lung cancer patients: a cohort study of the U.S. SEER database